Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients

Abstract

Objective: Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as type 1 diabetes, resulting in unnecessary treatment with insulin. A screening approach for monogenic diabetes is needed to accurately select suitable patients for expensive diagnostic genetic testing. We used C-peptide and islet autoantibodies, highly sensitive and specific biomarkers for discriminating type 1 from non-type 1 diabetes, in a biomarker screening pathway for monogenic diabetes.

Research design and methods: We studied patients diagnosed at age 30 years or younger, currently younger than 50 years, in two U.K. regions with existing high detection of monogenic diabetes. The biomarker screening pathway comprised three stages: 1) assessment of endogenous insulin secretion using urinary C-peptide/creatinine ratio (UCPCR); 2) if UCPCR was ≥0.2 nmol/mmol, measurement of GAD and IA2 islet autoantibodies; and 3) if negative for both autoantibodies, molecular genetic diagnostic testing for 35 monogenic diabetes subtypes.

Results: A total of 1,407 patients participated (1,365 with no known genetic cause, 34 with monogenic diabetes, and 8 with cystic fibrosis-related diabetes). A total of 386 out of 1,365 (28%) patients had a UCPCR ≥0.2 nmol/mmol, and 216 out of 386 (56%) were negative for GAD and IA2 and underwent molecular genetic testing. Seventeen new cases of monogenic diabetes were diagnosed (8 common Maturity Onset Diabetes of the Young [Sanger sequencing] and 9 rarer causes [next-generation sequencing]) in addition to the 34 known cases (estimated prevalence of 3.6% [51/1,407] [95% CI 2.7-4.7%]). The positive predictive value was 20%, suggesting a 1-in-5 detection rate for the pathway. The negative predictive value was 99.9%.

Conclusions: The biomarker screening pathway for monogenic diabetes is an effective, cheap, and easily implemented approach to systematically screening all young-onset patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed at age 30 years or younger.

Trial registration: ClinicalTrials.gov NCT01238380.

Conflict of interest statement

Declaration of interests: No conflicts of interest.

BS had full access to all the data in the study and had final responsibility for the decision to submit for publication

© 2017 by the American Diabetes Association.

Figures

Figure 1

The UNITED biomarker screening pathway to investigate etiology of diabetes in patients diagnosed ≤30y: Genetic testing is carried out on all patients who have endogenous insulin (UCPCR≥0.2nmol/mmol) and who do not have either GAD or IA2 islet autoantibodies. Patients without endogenous insulin or have GAD and/or IA2 islet autoantibodies are classed as having Type 1 diabetes.

Figure 2

Flow chart of patients recruited as part of UNITED. Biomarker screening pathway in 1376 patients with no known genetic cause for their diabetes in Exeter and Tayside. 11 dropped out. 17 new cases of monogenic diabetes detected (*one case identified through exome sequencing)